SPL
Director Trades
| Date | Director | Value |
|---|---|---|
| 4/11/24 | R. Thomas | $28,000 |
Company News
Starpharma and Radiopharm Theranostics Partner to Develop Novel Radiotherapy Asset
Starpharma Holdings (ASX: SPL) has entered into a research and option partnership with Radiopharm Theranostics (ASX: RAD) to develop and manufacture a dendrimer drug conjugate incorporating a radiopharmaceutical molecule to target certain cancers. The partnership, which follows six months of preliminary research under Starpharma’s Star Navigator drug development program, will see Radiopharm pay Starpharma a $500,000 for an […]
Starpharma Partners with Genentech to Develop Innovative Cancer Therapies Using DEP Technology
Starpharma Holdings (ASX: SPL) has signed a collaboration and licence agreement with US-based company Genentech to develop innovative cancer therapies leveraging Starpharma’s proprietary DEP (dendrimer-enhanced product) drug delivery platform. Dendrimers are precise, synthetically-manufactured molecules with unique properties – including size, structure, a high degree of branching, polyvalency, and water solubility – that can be advantageous […]
Starpharma’s DEP irinotecan shows promising efficacy in Phase 2 advanced cancer trials
Starpharma (ASX: SPL) has announced positive anti-tumour efficacy results from a Phase 2 clinical trial of its lead candidate DEP irinotecan in heavily pre-treated patients with a range of difficult-to-treat advanced and metastatic cancers. DEP irinotecan is a novel patented nanoparticle formulation of SN38, the active metabolite of the widely-used anti-cancer drug irinotecan (marketed as […]
Starpharma and Medicxi partner to create UK-based oncology company called Petalion Therapeutics
Australian biotech Starpharma Holdings (ASX: SPL) has entered into a strategic partnership with UK life sciences investment firm Medicxi to establish a UK-based company known as Petalion Therapeutics. Petalion will initially focus on developing novel targeted dendrimer-drug conjugate therapies for the treatment of cancers with unmet needs, utilising Starpharma’s proprietary DEP (dendrimer enhanced product) platform […]
Starpharma’s DEP irinotecan candidate has positive impact on human pancreatic cancer in mice
Starpharma (ASX: SPL) reported its DEP irinotecan candidate has induced “complete tumour regression” when trialled on mouse xenograft models with human pancreatic cancer. During the study, when Starpharma’s DEP irinotecan was used on human pancreatic tumour models, it resulted in complete tumour regression and 100% survival. This compares to existing drug Camptosar, which is a […]
Starpharma sells Agrochemicals business to Agrium for $35M
Starpharma Holdings (ASX: SPL) has completed a transaction to sell its agrochemicals and Priostar® business (Starpharma Agrochemicals) to Agrium, Inc. (NYSE: AGU, TSE: AGU) for A$35 million in cash consideration. The Starpharma Agrochemical business will be operated by Agrium’s wholly-owned subsidiary, Loveland Products, Inc. Starpharma Agrochemicals is comprised of key patents and technical know-how as […]